Cited by 189Adrenal and Paraganglionic TumorsPituitary Gland Disorders and TreatmentsSarcoma Diagnosis and Treatment

Radiotherapy in adrenocortical carcinoma

Open access
Polat, Buelent, Fassnacht, Martin, Pfreundner, Leo, Guckenberger, Matthias, Bratengeier, Klaus, Johanssen, Sarah, Kenn, Werner, Hahner, Stefanie +2 more·2009·Cancer

Abstract

Adrenocortical carcinoma (ACC) is a rare malignancy, and patients with ACC have a poor prognosis. Even after radical surgery, up to 85% of patients develop recurrent disease. Systemic treatment options still have limited efficacy. Because the role of radiotherapy is not defined well and because ACC often is considered radioresistant, the authors reviewed the available data on radiotherapy for ACC. Original articles and reviews were identified using a PubMed search strategy that included the period up to July 2008. Ten articles were identified that covered radiotherapy in a total of 129 patients with ACC (64 patients received postoperative irradiation, and 65 patients received palliative therapy for advanced disease). In addition, 26 patients were identified in the German ACC Registry who received palliative radiotherapy. Furthermore, patterns of failure after adjuvant radiotherapy were investigated, and the authors provided recommendations for patient selection, treatment planning, and treatment protocols. In an adjuvant setting, postoperative radiotherapy was able to prevent local recurrence in the majority of patients. In those with advanced disease, a response to radiotherapy was observed in 57% of patients who received palliative radiotherapy. Therefore, the authors concluded that radiotherapy may play an important role in the care of patients with ACC. Until better evidence is available, the authors recommended the following approach: Adjuvant radiotherapy to the tumor bed should be considered in patients at high risk for local recurrence (eg, incomplete/R1 resection); a total dose of >40 grays (Gy) with single fractions of 1.8 Gy to 2 Gy should be administered (including a boost volume to reach from 50 Gy to 60 Gy in individual patients); and radiotherapy in a palliative setting may be used for symptomatic metastases to bone, brain, or vena cava obstruction. With state-of-the-art technology, acute and long-term toxicities mostly were mild to moderate. However, the authors concluded that prospective investigations would be required to fully define the therapeutic potential of this important treatment option.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.24331

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Radiotherapy has been shown in several recent series to offer a significant improvement in disease control in both adjuvant and palliative settings, although such improvement has not been universally demonstrated.

    “Although traditionally considered ineffective for ACC (327–331), radiotherapy has been shown in several recent series to offer a significant improvement in disease control in both the adjuvant and palliative settings (247, 332–337), although such an improvement has not been universally demonstrated (338).”

    From Adrenocortical carcinoma (2014) · cites this paper as [336]

  • Polat et al reported 22 patients with painful osseous metastases, 17 (77%) experienced adequate palliation of pain after radiotherapy with dosages totaling 10 to 60 Gy.

    “In this series, 22 patients had painful osseous metastases, and 17 patients (77%) experienced adequate palliation of pain after radiotherapy with dosages totaling 10 to 60 Gy.”

    From Adrenocortical carcinoma (2014) · cites this paper as [336]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 5

  1. Allolio B, Hahner S, Weismann D, Fassnacht M. Manage- ment of adrenocortical carcinoma. Clin Endocrinol (Oxf). 2004;60:273-287.
  2. Allolio B, Fassnacht M. Clinical review: adrenocortical car- cinoma: clinical update. J Clin Endocrinol Metab. 2006;91: 2027-2037.
  3. Guckenberger M, Wilbert J, Krieger T, et al. Four-dimen- sional treatment planning for stereotactic body radiother- apy. Int J Radiat Oncol Biol Phys. 2007;69:276-285.
  4. Konski A, Feigenberg S, Chow E. Palliative radiation ther- apy. Semin Oncol. 2005;32:156-164.
  5. Soffen EM, Solin LJ, Rubenstein JH, Hanks GE. Palliative radiotherapy for symptomatic adrenal metastases. Cancer. 1990;65:1318-1320.

Cited by

Sorted by citations

Authors
Polat, B., Fassnacht, M., Pfreundner, L., Guckenberger, M., Bratengeier, K., Johanssen, S., Kenn, W., Hahner, S., Allolio, B., & Flentje, M.
Affiliations
University of Würzburg (DE)
Venue
Cancer
Publisher
Wiley
Published
2009-04-28
Volume
115
Issue
13
Pages
2816-2823
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2050111607
Cited by
189
References
43
Citations by year
2026: 2 · 2025: 6 · 2024: 6 · 2023: 9 · 2022: 11 · 2021: 18 · 2020: 13 · 2019: 7 · 2018: 15 · 2017: 7 · 2016: 6 · 2015: 19 · 2014: 9 · 2013: 12 · 2012: 20
FWCI
16.52
Type
journal article
Language
en
Open access
Locations
  • Cancer (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
Keywords
adrenocortical carcinoma, radiotherapy, adjuvant radiotherapy, postoperative radiotherapy, palliative radiotherapy, local recurrence, incomplete resection, metastasis, vena cava obstruction, radioresistance (biology), treatment toxicity, dose fractionation
MeSH terms
Adrenal Cortex Neoplasms, Combined Modality Therapy, Humans, Lymphatic Metastasis, Neoplasm Recurrence, Local, Palliative Care, Radiation Injuries, Recurrence, Treatment Outcome, Adrenocortical Carcinoma, Radiotherapy, Adjuvant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review